W-L FreshBurst Listerine Expanded Anticaries Clinical Test Urged By FDA
This article was originally published in The Tan Sheet
Executive Summary
Potential changes to the anticaries and antiplaque/antigingivitis monographs to allow a crossover product must be accompanied by stronger clinical studies than proposed by Warner-Lambert for FreshBurst Listerine With Fluoride, FDA advised the company at an OTC drug "feedback" meeting in Rockville, Md. June 6.
You may also be interested in...
W-L Listerine Anticaries Rinse Gingivitis Assessment Required - FDA
Acceptance of plaque reduction as the sole outcome of an experimental gingivitis model conducted to demonstrate the antiplaque/antigingivitis activities of Pfizer/Warner-Lambert's Listerine anticaries mouthrinse would be "premature," FDA tells company.
W-L Listerine Anticaries Rinse Gingivitis Assessment Required - FDA
Acceptance of plaque reduction as the sole outcome of an experimental gingivitis model conducted to demonstrate the antiplaque/antigingivitis activities of Pfizer/Warner-Lambert's Listerine anticaries mouthrinse would be "premature," FDA tells company.
W-L Listerine Anticaries Fluoride Rinse Formula Change Proposed To FDA
Warner-Lambert has changed its proposed fluoride-containing oral anticaries/antiplaque/antigingivitis rinse to a .02% sodium fluoride formula to reflect results from recently conducted market research on taste, the company says in comments submitted to FDA May 15.